ClinicalTrials.gg
CompletedNCT02629562Updated Oct 13, 2017

Pharmacokinetic and Pharmacodynamics of B12019 and Neulasta® in Healthy Subjects

A Phase 1 interventional study of B12019 and Neulasta in Clinical Pharmacology, sponsored by Cinfa Biotech. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-10-13.

Sponsored by Cinfa Biotech (part of Mundipharma) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
172
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

Multi-centre, double-blind, randomised, 2-way cross-over study to investigate the PK and PD of B12019 as compared to Neulasta® administered as a single subcutaneous (s.c.) dose in healthy male subjects. B12019 or Neulasta will be administered by s.c. injection.

02

Conditions studied

  • Clinical Pharmacology
03

In context

Lead sponsor

Cinfa Biotech is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects
  • Age ≥18 and ≤55 years
  • 22.0 - 28.0 kg/m2
  • Non-smokers for at least 6 months prior to study start
  • General good health, based on a comprehensive medical history and physical examination
  • Adequate organ function and normal laboratory values (unless the investigator considers an abnormality to be clinically not relevant)
  • Negative surface antigen (HBsAg), antibody and (HIV) tests at screening
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Known to Escherichia coli derived proteins, pegfilgrastim, filgrastim or any other component of B12019 or Neulasta®
  • Previous exposure to filgrastim or pegfilgrastim
  • History of drug or alcohol abuse
  • Blood donations in the past 3 months prior to study start, or bone marrow or stem cell donor in the past 12 months (first dose)
  • Medical history of haematological disease, including sickle cell disorders
  • Recent infection (within 1 week prior to first dose)
  • Relevant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine, inflammatory or neurological diseases, that in the opinion of the investigator may interfere with the aim of the study
  • Participation in an interventional or Phase I study in the last 3 months or is current a follow-up visit schedule for any study, or has participation in more than three studies of experimental drug products in the past 12 months prior to screening
  • Subjects with ANC values outside the normal laboratory range at screening
  • Use of prescription or over-the-counter drugs including vitamins within 4 weeks of first dosing
  • Abnormalities in
  • Signs of dermatitis or skin abnormalities affecting the administration area and surroundings
  • History of cancer
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
172 participants (actual)

Study arms

  • Experimental
    Arm 1

    first dosing: single dose of 6mg of B12019 administered subcutaneously, second dosing: single dose of 6mg of Neulasta administered subcutaneously

    Biological: B12019 and Neulasta

  • Experimental
    Arm 2

    first dosing: single dose of 6mg of Neulasta administered subcutaneously, second dosing: single dose of 6mg of B12019 administered subcutaneously

    Biological: B12019 and Neulasta

Interventions

  • BiologicalB12019 and Neulasta

    Drug page: Pegfilgrastim

    GCSF, Growth Colony Stimulating Factor

06

What researchers measure

Primary outcomes

  1. PK parameter AUC0-last

    Area under the plasma concentration-time curve

    Time frame: 6 weeks

  2. PK parameter Cmax

    Maximum observed drug concentration

    Time frame: 6 weeks

  3. PD parameter ANC

    AUEC0-last

    Time frame: 6 weeks

07

Study locations

1 site
  • Nuvisan GmbH
    Neu-Ulm, 89231, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2015 and a primary completion of Jul 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2015
First posted
Dec 14, 2015
Start
Nov 2015
Primary completionActual
Jul 2016
Last update
Oct 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02629562
Lead sponsor
Cinfa Biotech
Responsible party
Sponsor
First posted
Dec 14, 2015
Start date
Nov 2015
Primary completion
Jul 2016
Last update
Oct 13, 2017

Study contacts

Michael Lissy, MD
principal investigator · Nuvisan GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegfilgrastim

Start the discussion